Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M382Revenue (TTM) $M36.2Net Margin (%)-291.4Altman Z-Score-8.9
Enterprise Value $M327EPS (TTM) $-0.4Operating Margin %-275.6Piotroski F-Score1
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-291.4Higher ROA y-yN
Price/Book28.010-y EBITDA Growth Rate %-29.7Quick Ratio2.4Cash flow > EarningsY
Price/Sales10.55-y EBITDA Growth Rate %-45.8Current Ratio2.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-39.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-179.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M243ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2016-03-31 Sold Out $1.41 - $1.97
($1.61)
$ 1.57-2%Sold Out0
ARNAKen Fisher 2015-12-31 Add$1.7 - $2.4
($2.04)
$ 1.57-23%Add 0.91%11,100
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
($5.22)
$ 1.57-70%New holding11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
($1.7)
$ 1.57-8%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
($1.58)
$ 1.57-1%New holding13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
White Christine AnnaDirector 2016-06-13Sell18,728$1.99-19.6view
WOODS RANDALL EDirector 2015-03-30Sell76,268$4.49-64.37view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell70,000$5-68view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-74.44view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-70.86view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-72.65view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-72.65view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-77.3view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-77.14view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-74.64view

Quarterly/Annual Reports about ARNA:

News about ARNA:

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Arena Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
Arena Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
Aug 29, 2016With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman as its Chief Financial... Aug 29 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Aug 25 2016
ETF’s with exposure to Arena Pharmaceuticals, Inc. : August 23, 2016 Aug 23 2016
ARENA PHARMACEUTICALS INC Financials Aug 18 2016
Biotech Industry on the Upswing after Rocky Start to 2016 Aug 17 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 15 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer Aug 15 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer Aug 15 2016
ETF’s with exposure to Arena Pharmaceuticals, Inc. : August 11, 2016 Aug 11 2016
Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 Aug 10 2016
Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y Aug 09 2016
ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 09 2016
How Will Arena Pharmaceuticals (ARNA) Stock React to Q2 Miss? Aug 08 2016
Arena Pharmaceuticals reports 2Q loss Aug 08 2016
Arena Pharmaceuticals reports 2Q loss Aug 08 2016
Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 08 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 08 2016
Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 08 2016
What to Expect in Arena Pharmaceuticals Earnings? Aug 08 2016
Q2 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close Aug 08 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)